We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Idorsia Ltd | LSE:0RQE | London | Ordinary Share | CH0363463438 | IDORSIA N ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
1.879 | 2.076 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
17:33:56 | O | 120 | 1.439 | CHF |
Date | Time | Source | Headline |
---|---|---|---|
17/9/2024 | 16:45 | UKREG | Idorsia continues to further the science of sleep and insomnia with new.. |
05/9/2024 | 16:45 | UKREG | New data on aprocitentan to be presented at the AHA Hypertension Scientific.. |
02/9/2024 | 16:45 | UKREG | Amended terms of Idorsia’s 2024 convertible bonds become effective |
25/7/2024 | 06:00 | UKREG | Idorsia announces financial results for the first half 2024 |
18/7/2024 | 16:45 | UKREG | Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and.. |
01/7/2024 | 06:00 | UKREG | Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA.. |
28/6/2024 | 16:45 | UKREG | Higher cantonal composition authority issues written court decision in.. |
25/6/2024 | 16:45 | UKREG | Higher cantonal composition authority approved the amendments to the terms.. |
21/6/2024 | 06:00 | UKREG | Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix.. |
13/6/2024 | 10:00 | UKREG | Idorsia holds its Annual General Meeting of Shareholders |
Idorsia (0RQE) Share Charts1 Year Idorsia Chart |
|
1 Month Idorsia Chart |
Intraday Idorsia Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions